Brief: Aeterna Zentaris Announces Initiation Of Its Preclinical Program For Treatment Of Primary Hypoparathyroidism

COSCIENS Biopharma

11/03/2021 13:20

March 11 (Reuters) - Aeterna Zentaris Inc  AEZS.TO :
    * AETERNA ZENTARIS CONTINUES TO DEMONSTRATE PIPELINE
EXPANSION -
ANNOUNCES INITIATION OF ITS PRECLINICAL PROGRAM FOR POTENTIAL
TREATMENT OF PRIMARY HYPOPARATHYROIDISM
    * AETERNA - CO OBTAINED WORLDWIDE RIGHTS TO DEVELOP,
MANUFACTURE,
COMMERCIALIZE PTH FUSION POLYPEPTIDES COVERED BY LICENSED
PATENTS FOR ALL HUMAN USES
    * AETERNA -OBTAINED UP-FRONT CASH PAYMENT OF £100,000,
MILESTONE
PAYMENTS TO BE PAID ON ACHIEVEMENT OF CERTAIN DEVELOPMENT,
REGULATORY, SALES MILESTONES
    * AETERNA - CO TO BE PAID LOW SINGLE DIGIT ROYALTY PAYMENTS
ON NET
SALES OF THOSE PRODUCTS, CERTAIN FEES PAYABLE IN CONNECTION WITH
SUBLICENSING
    * AETERNA ZENTARIS - CO ENGAGED UNIVERSITY OF SHEFFIELD, UK,
UNDER
A RESEARCH CONTRACT TO CONDUCT CERTAIN RESEARCH ACTIVITIES TO BE
FUNDED BY CO

Source text for Eikon:  ID:nGNXbQlbWt 
Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))